


a stereoisomer, enantiomer or tautomer thereof, a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof or.

Of the compounds of Formula (I), an embodiment provides compound of Formula (IA):




Formula (IA)

wherein,

A, A¹, A², R¹, R³, and R⁴ are as defined above.

Of the compounds of Formula (IA), an embodiment provides compounds of Formula (IA1):




Formula (IA1)

wherein:

R¹, R², R³, and R⁴ are as defined above.


Of the compounds of Formula (IA), another embodiment provides compounds of Formula (IA2):



Formula (IA2)

wherein, R¹, R², R³, and R⁴ are as defined above.

Of the compounds of Formula (IA), another embodiment provides compounds of Formula (IA3):




Formula (IA3)

wherein, R¹, R², R³, and R⁴ are as defined above.

CLAIMS


WHAT IS CLAIMED IS

1. A compound of Formula (I):



Formula (I)

wherein:



W is

each A, A¹ and A² is the same or different and independently -N=, -CR⁵=, or -O-;

L is a heteroaryl, heterocyclyl, -N(R⁶)-, -O-, -C(O)-, -C(O)O-, -S(O)_t- where t is 0, 1, or 2, -CON(R⁶)-, -N(R⁶)CO-, -SO₂N(R⁶)-, or -N(R⁶)CON(R⁶)-; provided that when L is heteroaryl, L is not pyridinyl, pyrazinyl or thienyl;

R¹ is alkyl, cycloalkyl, cycloalkylalkyl, haloalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, or heteroarylalkyl;

R² is hydrogen, heterocyclyl, heterocyclylalkyl, cycloalkyl, alkyl, aralkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, or aryl;


each R³ and R⁴ is the same or different and independently selected from hydrogen, alkyl, aralkyl, alkenyl, aralkenyl, alkynyl, aralkynyl, cycloalkyl, cycloalkylalkyl, halo, or haloalkyl;

R⁵, at each occurrence, is hydrogen, alkyl, aralkyl, cycloalkyl, cycloalkylalkyl, halo, or haloalkyl; and

R⁶ is hydrogen, alkyl, cycloalkyl, cycloalkylalkyl, or haloalkyl, a stereoisomer, enantiomer or tautomer thereof, a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof.


2. The compound of claim 1 wherein L is heteroaryl.
3. The compound of claim 1 or claim 2 wherein L is N-heteroaryl.

4. The compound of any one of claims 1-3 wherein L is divalent pyrazolyl moiety and the compound is represented by Formula (IA):



Formula (IA)

5. The compound of any one of claims 1-4, represented by Formula (IA1):



Formula (IA1)

6. The compound of claim 5 wherein R¹ is aryl, heteroaryl, cycloalkyl or heterocyclyl.

7. The compound of claim 6 wherein R¹ is a phenyl or substituted phenyl.

8. The compound of claim 6 or claim 7 wherein R² is aryl, heteroaryl, cycloalkyl or heterocyclyl.

9. The compound of any one of claims 6-8, wherein R² is piperidinyl, substituted piperidinyl, tetrahydropyranyl, or cyclohexyl.

10. The compound of any one of claims 6-9, wherein each of R³ and R⁴ is hydrogen.

11. The compound of any one of claims 6-9 wherein each of R³ and R⁴ is hydrogen;

R¹ is phenyl or substituted phenyl; and

R² is 1-piperidin-4-yl or substituted 1-piperidin-4-yl.

12. The compound of claim 11 being:

tert-butyl-4-(4-(6-amino-5-(5-phenyloxazol-2-yl)pyridin-3-yl)-1*H*-pyrazol-1-yl)piperidine-1-carboxylate;
3-(5-phenyloxazol-2-yl)-5-(1-(piperidin-4-yl)-1*H*-pyrazol-4-yl)pyridin-2-amine;
tert-butyl 4-(4-(6-amino-5-(5-(4-chlorophenyl)oxazol-2-yl)pyridin-3-yl)-1*H*-pyrazol-1-yl)piperidine-1-carboxylate;
3-(5-(4-chlorophenyl)oxazol-2-yl)-5-(1-(piperidin-4-yl)-1*H*-pyrazol-4-yl)pyridin-2-amine;
1-(4-(4-(6-amino-5-(5-(4-chlorophenyl)oxazol-2-yl)pyridin-3-yl)-1*H*-pyrazol-1-yl)piperidin-1-yl)ethanone;
(4-(4-(6-amino-5-(5-(4-chlorophenyl)oxazol-2-yl)pyridin-3-yl)-1*H*-pyrazol-1-yl)piperidin-1-yl)(cyclopropyl)methanone;
3-(5-(3-chlorophenyl)oxazol-2-yl)-5-(1-(piperidin-4-yl)-1*H*-pyrazol-4-yl)pyridin-2-amine;
1-(4-(4-(6-amino-5-(5-(3-chlorophenyl)oxazol-2-yl)pyridin-3-yl)-1*H*-pyrazol-1-yl)piperidin-1-yl)ethanone;
3-(5-(3-chlorophenyl)oxazol-2-yl)-5-(1-(1-methylpiperidin-4-yl)-1*H*-pyrazol-4-yl)pyridin-2-amine;
(4-(4-(6-amino-5-(5-(3-chlorophenyl)oxazol-2-yl)pyridin-3-yl)-1*H*-pyrazol-1-yl)piperidin-1-yl)(cyclopropyl)methanone;
(4-(4-(6-amino-5-(5-(3-chlorophenyl)oxazol-2-yl)pyridin-3-yl)-1*H*-pyrazol-1-yl)piperidin-1-yl)(phenyl)methanone;
1-(4-(4-(6-amino-5-(5-(3-chlorophenyl)oxazol-2-yl)pyridin-3-yl)-1*H*-pyrazol-1-yl)piperidin-1-yl)-2-phenylethanone;
(4-(4-(6-amino-5-(5-(4-chlorophenyl)oxazol-2-yl)pyridin-3-yl)-1*H*-pyrazol-1-yl)piperidin-1-yl)(phenyl)methanone;
1-(4-(4-(6-amino-5-(5-(4-chlorophenyl)oxazol-2-yl)pyridin-3-yl)-1*H*-pyrazol-1-yl)piperidin-1-yl)-2-phenylethanone;
3-(5-(4-chlorophenyl)oxazol-2-yl)-5-(1-(1-methylpiperidin-4-yl)-1*H*-pyrazol-4-yl)pyridin-2-amine;
1-(4-(4-(6-amino-5-(5-(3-chlorophenyl)oxazol-2-yl)pyridin-3-yl)-1*H*-pyrazol-1-yl)piperidin-1-yl)-2,2-dimethylpropan-1-one;

(4-(4-(6-amino-5-(5-(3-chlorophenyl)oxazol-2-yl)pyridin-3-yl)-1*H*-pyrazol-1-yl)piperidin-1-yl)(4-fluorophenyl)methanone; or
5-(1-(1-ethylpiperidin-4-yl)-1*H*-pyrazol-4-yl)-3-(5-phenyloxazol-2-yl)pyridin-2-amine.

13. The compound of any one of claims 6-9 wherein
each of R³ and R⁴ is hydrogen;
R¹ is phenyl or substituted phenyl; and
R² is tetrahydropyranyl.

14. The compound of claim 13 being:
3-(5-phenyloxazol-2-yl)-5-(1-(tetrahydro-2pyran-4-yl)-1*H*-pyrazol-4-yl)pyridin-2-amine; or
3-(5-(4-chlorophenyl)oxazol-2-yl)-5-(1-(tetrahydro-2pyran-4-yl)-1*H*-pyrazol-4-yl)pyridin-2-amine.


15. The compound of any one of claims 6-9 wherein
each of R³ and R⁴ is hydrogen;
R¹ is phenyl or substituted phenyl; and
R² is cyclohexyl.

16. The compound of claim 15 being:
3-(5-(3-chlorophenyl)oxazol-2-yl)-5-(1-cyclohexyl-1*H*-pyrazol-4-yl)pyridin-2-amine;
3-(5-(4-chlorophenyl)oxazol-2-yl)-5-(1-cyclohexyl-1*H*-pyrazol-4-yl)pyridin-2-amine;
or
5-(1-cyclohexyl-1*H*-pyrazol-4-yl)-3-(5-phenyloxazol-2-yl)pyridin-2-amine.

17. The compound of any one of claims 6-9, wherein
each of R³ and R⁴ is hydrogen;
R¹ is heteroaryl; and
R² is heterocyclyl.

18. The compound of claim 17 being 5-(1-(piperidin-4-yl)-1*H*-pyrazol-4-yl)-3-(5-(pyridin-3-yl)oxazol-2-yl)pyridin-2-amine.

19. The compound of any one of claims 1-4, represented by Formula (IA2):



Formula (IA2)


20. The compound of claim 19 wherein R¹ is aryl, heteroaryl, cycloalkyl or heterocyclyl.

21. The compound of claim 19 or 20 wherein R² is aryl, heteroaryl, cycloalkyl or heterocyclyl.

22. The compounds of any one of claims 19-21 wherein:
each of R³ and R⁴ is hydrogen;
R¹ is phenyl or substituted phenyl; and
R² is piperidinyl, substituted piperidinyl, tetrahydropyranyl or cyclohexyl.

23. The compound of claim 22 being:
5-(1-cyclohexyl-1H-pyrazol-4-yl)-3-(5-phenylisoxazol-3-yl)pyridin-2-amine;
3-(5-phenylisoxazol-3-yl)-5-(1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine;
3-(5-phenylisoxazol-3-yl)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; or
5-(1-(1-methylpiperidin-4-yl)-1H-pyrazol-4-yl)-3-(5-phenylisoxazol-3-yl)pyridin-2-amine.

24. The compound of any one of claims 1-4, represented by Formula (IA3):



Formula (IA3)


25. The compound of claim 24 wherein R¹ is aryl, heteroaryl, cycloalkyl or heterocyclyl.

26. The compound of claim 24 or 25, wherein R² is aryl, heteroaryl, cycloalkyl or heterocyclyl.

27. The compound of any one of claims 24-26, wherein each of R³ and R⁴ is hydrogen; R¹ is phenyl or substituted phenyl; and R² is piperidinyl, substituted piperidinyl, tetrahydropyranyl or cyclohexyl.

28. The compound of claim 27 being:
3-(5-phenylfuran-2-yl)-5-(1-(piperidin-4-yl)-1*H*-pyrazol-4-yl)pyridin-2-amine;
5-(1-(1-methylpiperidin-4-yl)-1*H*-pyrazol-4-yl)-3-(5-phenylfuran-2-yl)pyridin-2-amine;
5-(1-cyclohexyl-1*H*-pyrazol-4-yl)-3-(5-phenylfuran-2-yl)pyridin-2-amine; or
3-(5-phenylfuran-2-yl)-5-(1-(tetrahydro-2*H*-pyran-4-yl)-1*H*-pyrazol-4-yl)pyridin-2-amine.

29. The compound of any one of claims 1-4, represented by Formula (IA4):



30. The compound of claim 29, wherein R¹ is aryl, heteroaryl, cycloalkyl, heterocyclyl, aralkyl, or cycloalkylalkyl.

31. The compound of claim 30 wherein R¹ is a phenyl, substituted phenyl, benzyl or cyclopropylalkyl.

32. The compound of claim 30 wherein R¹ is a pyridinyl, substituted pyridinyl, pyrazinyl, substituted pyrazinyl, thiazolyl, or substituted thiazolyl.

33. The compound of any one of claims 29-32, wherein R² is hydrogen, aryl, heteroaryl, cycloalkyl or heterocyclyl.

34. The compound of claim 33 wherein R² is piperidinyl or substituted piperidinyl, tetrahydropyranyl or hydrogen.

35. The compound of claim 30 wherein:

each of R³ and R⁴ is hydrogen;

R¹ is phenyl or substituted phenyl; and

R² is piperidinyl or substituted piperidinyl.

36. The compound of claim 35 being:

tert-butyl 4-(4-(6-amino-5-(5-phenyl-1,3,4-oxadiazol-2-yl)pyridin-3-yl)-1*H*-pyrazol-1-yl)piperidine-1-carboxylate;

3-(5-(5-phenyl-1,3,4-oxadiazol-2-yl)-5-(1-(piperidin-4-yl)-1*H*-pyrazol-4-yl)pyridin-2-amine;

3-(5-(2,6-dichloro-3-fluorophenyl)-1,3,4-oxadiazol-2-yl)-5-(1-(piperidin-4-yl)-1*H*-pyrazol-4-yl)pyridin-2-amine;

3-(5-(4-(*tert*-butyl)phenyl)-1,3,4-oxadiazol-2-yl)-5-(1-(piperidin-4-yl)-1*H*-pyrazol-4-yl)pyridin-2-amine;

tert-butyl 4-(4-(6-amino-5-(5-(4-(*tert*-butyl)phenyl)-1,3,4-oxadiazol-2-yl)pyridin-3-yl)-1*H*-pyrazol-1-yl)piperidine-1-carboxylate;

3-(5-(2,5-difluorophenyl)-1,3,4-oxadiazol-2-yl)-5-(1-(piperidin-4-yl)-1*H*-pyrazol-4-yl)pyridin-2-amine;

3-(5-(2,6-dichlorophenyl)-1,3,4-oxadiazol-2-yl)-5-(1-(piperidin-4-yl)-1*H*-pyrazol-4-yl)pyridin-2-amine;

tert-butyl 4-(4-(6-amino-5-(5-(2,6-dichlorophenyl)-1,3,4-oxadiazol-2-yl)pyridin-3-yl)-1*H*-pyrazol-1-yl)piperidine-1-carboxylate;

3-(5-(4-fluorophenyl)-1,3,4-oxadiazol-2-yl)-5-(1-(piperidin-4-yl)-1*H*-pyrazol-4-yl)pyridin-2-amine;

tert-butyl 4-(4-(6-amino-5-(5-(4-fluorophenyl)-1,3,4-oxadiazol-2-yl)pyridin-3-yl)-1*H*-pyrazol-1-yl)piperidine-1-carboxylate;

1-(4-(4-(6-amino-5-(5-(2,6-dichlorophenyl)-1,3,4-oxadiazol-2-yl)pyridin-3-yl)-1*H*-pyrazol-1-yl)piperidin-1-yl)ethanone;
 3-(5-(2,6-dichlorophenyl)-1,3,4-oxadiazol-2-yl)-5-(1-(1-methylpiperidin-4-yl)-1*H*-pyrazol-4-yl)pyridin-2-amine;
 1-(4-(4-(6-amino-5-(5-(2,6-dichlorophenyl)-1,3,4-oxadiazol-2-yl)pyridin-3-yl)-1*H*-pyrazol-1-yl)piperidin-1-yl)-4-methylpentan-1-one;
 (4-(4-(6-amino-5-(5-(2,6-dichlorophenyl)-1,3,4-oxadiazol-2-yl)pyridin-3-yl)-1*H*-pyrazol-1-yl)piperidin-1-yl)(cyclopropyl)methanone;
 (4-(4-(6-amino-5-(5-(2,6-dichlorophenyl)-1,3,4-oxadiazol-2-yl)pyridin-3-yl)-1*H*-pyrazol-1-yl)piperidin-1-yl)(phenyl)methanone;
 1-(4-(4-(6-amino-5-(5-(2,6-dichlorophenyl)-1,3,4-oxadiazol-2-yl)pyridin-3-yl)-1*H*-pyrazol-1-yl)piperidin-1-yl)-2-phenylethanone;
 3-(5-(2,6-dichlorophenyl)-1,3,4-oxadiazol-2-yl)-5-(1-(1-ethylpiperidin-4-yl)-1*H*-pyrazol-4-yl)pyridin-2-amine; or
 3-(5-(2,6-dichlorophenyl)-1,3,4-oxadiazol-2-yl)-5-(1-(1-dodecylpiperidin-4-yl)-1*H*-pyrazol-4-yl)pyridin-2-amine.

37. The compound of claim 30 wherein:
 each of R³ and R⁴ is hydrogen;
 R¹ is heteroaryl or substituted heteroaryl; and
 R² is piperidinyl or substituted piperidinyl.

38. The compound of claim 37 being:
tert-butyl 4-(4-(6-amino-5-(5-(pyrazin-2-yl)-1,3,4-oxadiazol-2-yl)pyridin-3-yl)-1*H*-pyrazol-1-yl)piperidine-1-carboxylate;
tert-butyl 4-(4-(6-amino-5-(5-(pyridin-2-yl)-1,3,4-oxadiazol-2-yl)pyridin-3-yl)-1*H*-pyrazol-1-yl)piperidine-1-carboxylate;
 5-(1-(piperidin-4-yl)-1*H*-pyrazol-4-yl)-3-(5-(pyrazin-2-yl)-1,3,4-oxadiazol-2-yl)pyridin-2-amine;
 5-(1-(piperidin-4-yl)-1*H*-pyrazol-4-yl)-3-(5-(pyridin-2-yl)-1,3,4-oxadiazol-2-yl)pyridin-2-amine;
tert-butyl 4-(4-(6-amino-5-(5-(thiazol-2-yl)-1,3,4-oxadiazol-2-yl)pyridin-3-yl)-1*H*-pyrazol-1-yl)piperidine-1-carboxylate;

5-(1-(piperidin-4-yl)-1*H*-pyrazol-4-yl)-3-(5-(thiazol-2-yl)-1,3,4-oxadiazol-2-yl)pyridin-2-amine;
 5-(1-(piperidin-4-yl)-1*H*-pyrazol-4-yl)-3-(5-(pyridin-3-yl)-1,3,4-oxadiazol-2-yl)pyridin-2-amine;
tert-butyl 4-(4-(6-amino-5-(5-(pyridin-3-yl)-1,3,4-oxadiazol-2-yl)pyridin-3-yl)-1*H*-pyrazol-1-yl)piperidine-1-carboxylate;
tert-butyl 4-(4-(6-amino-5-(5-(4-(trifluoromethyl)-thiazol-2-yl)-1,3,4-oxadiazol-2-yl)pyridin-3-yl)-1*H*-pyrazol-1-yl)piperidine-1-carboxylate; or
 5-(1-(piperidin-4-yl)-1*H*-pyrazol-4-yl)-3-(5-(4-(trifluoromethyl)thiazol-2-yl)-1,3,4-oxadiazol-2-yl)pyridin-2-amine.

39. The compound of claim 30 wherein:
 each of R³ and R⁴ is hydrogen;
 R¹ is cycloalkylalkyl or aralkyl; and
 R² is piperidinyl or substituted piperidinyl.


40. The compound of claim 39 being:
tert-butyl 4-(4-(6-amino-5-(5-(cyclopropylmethyl)-1,3,4-oxadiazol-2-yl)pyridin-3-yl)-1*H*-pyrazol-1-yl)piperidine-1-carboxylate;
 3-(5-(cyclopropylmethyl)-1,3,4-oxadiazol-2-yl)-5-(1-(piperidin-4-yl)-1*H*-pyrazol-4-yl)pyridin-2-amine;
tert-butyl 4-(4-(6-amino-5-(5-benzyl-1,3,4-oxadiazol-2-yl)pyridin-3-yl)-1*H*-pyrazol-1-yl)piperidine-1-carboxylate; or
 3-(5-benzyl-1,3,4-oxadiazol-2-yl)-5-(1-(piperidin-4-yl)-1*H*-pyrazol-4-yl)pyridin-2-amine.

41. The compound of claim 30 wherein:
 each of R³ and R⁴ is hydrogen;
 R¹ is phenyl or substituted phenyl; and
 R² is hydrogen, cycloalkyl or tetrahydropyranyl

42. The compound of claim 41 being:
 3-(5-(2,6-dichlorophenyl)-1,3,4-oxadiazol-2-yl)-5-(1*H*-pyrazol-4-yl)pyridin-2-amine;
 3-(5-phenyl-1,3,4-oxadiazol-2-yl)-5-(1*H*-pyrazol-4-yl)pyridin-2-amine;

3-(5-(4-(*tert*-butyl)phenyl)-1,3,4-oxadiazol-2-yl)-5-(1*H*-pyrazol-4-yl)pyridin-2-amine;
 3-(5-(2,5-difluorophenyl)-1,3,4-oxadiazol-2-yl)-5-(1*H*-pyrazol-4-yl)pyridin-2-amine;
 3-(5-(4-fluorophenyl)-1,3,4-oxadiazol-2-yl)-5-(1*H*-pyrazol-4-yl)pyridin-2-amine;
 5-(1-cyclohexyl-1*H*-pyrazol-4-yl)-3-(5-(2,6-dichlorophenyl)-1,3,4-oxadiazol-2-yl)pyridin-2-amine;
 5-(1-cyclohexyl-1*H*-pyrazol-4-yl)-3-(5-phenyl-1,3,4-oxadiazol-2-yl)pyridin-2-amine;
 3-(5-(2,6-dichlorophenyl)-1,3,4-oxadiazol-2-yl)-5-(1-(tetrahydro-2*H*-pyran-4-yl)-1*H*-pyrazol-4-yl)pyridin-2-amine; or
 3-(5-phenyl-1,3,4-oxadiazol-2-yl)-5-(1-(tetrahydro-2*H*-pyran-4-yl)-1*H*-pyrazol-4-yl)pyridin-2-amine.

43. The compound of any one of claims 1-4, represented by Formula (IA5):



Formula (IA5)

44. The compound of claim 43 wherein R¹ is aryl; and R² is heterocyclyl.

45. The compound of claim 43 or claim 44 wherein R¹ is phenyl or substituted phenyl; and R² is hydrogen, piperidinyl, substituted piperidinyl, tetrahydropyranyl or cyclohexyl.

46. The compound of any one of claims 43-45 wherein:
 each of R³ and R⁴ is hydrogen;
 R¹ is phenyl or substituted phenyl;
 R² is piperidinyl or substituted piperidinyl.

47. The compound of claim 46 being:
 3-(3-phenyl-1,2,4-oxadiazol-5-yl)-5-(1-(piperidin-4-yl)-1*H*-pyrazol-4-yl)pyridin-2-amine;


1-(4-(4-(6-amino-5-(3-phenyl-1,2,4-oxadiazol-5-yl)pyridin-3-yl)-1*H*-pyrazol-1-yl)piperidin-1-yl)ethanone;
 (4-(4-(6-amino-5-(3-phenyl-1,2,4-oxadiazol-5-yl)pyridin-3-yl)-1*H*-pyrazol-1-yl)piperidin-1-yl)(cyclopropyl)methanone;
 5-(1-(1-methylpiperidin-4-yl)-1*H*-pyrazol-4-yl)-3-(3-phenyl-1,2,4-oxadiazol-5-yl)pyridin-2-amine;
 (4-(4-(6-amino-5-(3-phenyl-1,2,4-oxadiazol-5-yl)pyridin-3-yl)-1*H*-pyrazol-1-yl)piperidin-1-yl)(phenyl)methanone;
 1-(4-(4-(6-amino-5-(3-phenyl-1,2,4-oxadiazol-5-yl)pyridin-3-yl)-1*H*-pyrazol-1-yl)piperidin-1-yl)-2-phenylethanone;
 3-(3-(2,6-dichlorophenyl)-1,2,4-oxadiazol-5-yl)-5-(1-(piperidin-4-yl)-1*H*-pyrazol-4-yl)pyridin-2-amine;
 3-(3-(2,6-dichlorophenyl)-1,2,4-oxadiazol-5-yl)-5-(1-(1-methylpiperidin-4-yl)-1*H*-pyrazol-4-yl)pyridin-2-amine;
 3-(3-(2,6-dichlorophenyl)-1,2,4-oxadiazol-5-yl)-5-(1-(1-ethylpiperidin-4-yl)-1*H*-pyrazol-4-yl)pyridin-2-amine;
 5-(1-(1-ethylpiperidin-4-yl)-1*H*-pyrazol-4-yl)-3-(3-phenyl-1,2,4-oxadiazol-5-yl)pyridin-2-amine; or
 3-(3-(2,6-dichlorophenyl)-1,2,4-oxadiazol-5-yl)-5-(1-(1-dodecylpiperidin-4-yl)-1*H*-pyrazol-4-yl)pyridin-2-amine.

48. The compound of any one of claims 43-45 wherein:
 each of R³ and R⁴ is hydrogen;
 R¹ is phenyl or substituted phenyl;
 R² is hydrogen, tetrahydropyranyl or cyclohexyl.

49. The compound of claim 48 being:
 5-(1-cyclohexyl-1*H*-pyrazol-4-yl)-3-(3-phenyl-1,2,4-oxadiazol-5-yl)pyridin-2-amine;
 5-(1-cyclohexyl-1*H*-pyrazol-4-yl)-3-(3-(2,6-dichlorophenyl)-1,2,4-oxadiazol-5-yl)pyridin-2-amine;
 3-(3-phenyl-1,2,4-oxadiazol-5-yl)-5-(1-(tetrahydro-2*H*-pyran-4-yl)-1*H*-pyrazol-4-yl)pyridin-2-amine

3-(3-(2,6-dichlorophenyl)-1,2,4-oxadiazol-5-yl)-5-(1-(tetrahydro-2*H*-pyran-4-yl)-1*H*-pyrazol-4-yl)pyridin-2-amine; or
 3-(3-phenyl-1,2,4-oxadiazol-5-yl)-5-(1*H*-pyrazol-4-yl)pyridin-2-amine.

50. The compound of any one of claims 1-4, represented by Formula (IA6):



Formula (IA6)

51. The compound of claim 50 wherein R¹ is aryl, R² is heterocyclyl.

52. The compound of claim 50 or claim 51 wherein R¹ is phenyl or substituted phenyl; and R² is hydrogen, piperidinyl or substituted piperidinyl, tetrahydropyranyl or cyclohexyl.

53. The compound of any one of claims 50-52 wherein:
 each of R³ and R⁴ is hydrogen;

R¹ is phenyl or substituted phenyl; and

R² is hydrogen, piperidinyl, substituted piperidinyl, tetrahydropyranyl or cyclohexyl.

54. The compound of claim 53 being:

5-(1-cyclohexyl-1*H*-pyrazol-4-yl)-3-(5-phenyl-1,2,4-oxadiazol-3-yl)pyridin-2-amine;

3-(5-phenyl-1,2,4-oxadiazol-3-yl)-5-(1-(tetrahydro-2*H*-pyran-4-yl)-1*H*-pyrazol-4-yl)pyridin-2-amine;


3-(5-phenyl-1,2,4-oxadiazol-3-yl)-5-(1-(piperidin-4-yl)-1*H*-pyrazol-4-yl)pyridin-2-amine;

5-(1-(1-methylpiperidin-4-yl)-1*H*-pyrazol-4-yl)-3-(5-phenyl-1,2,4-oxadiazol-3-yl)pyridin-2-amine;

3-(5-(2,5-dichlorophenyl)-1,2,4-oxadiazol-3-yl)-5-(1-(piperidin-4-yl)-1*H*-pyrazol-4-yl)pyridin-2-amine;

3-(5-phenyl-1,2,4-oxadiazol-3-yl)-5-(1*H*-pyrazol-4-yl)pyridin-2-amine.

55. The compound of any one of claims 1-4, represented by Formula (IA7):




Formula (IA7)

56. The compound of claim 55 wherein R¹ is aryl and R² is heterocyclyl.

57. The compound of claim 55 or claim 56 being:
3-(5-(2,6-dichlorophenyl)-1,3,4-oxadiazol-2-yl)-5-(1-(piperidin-4-yl)-1*H*-pyrrol-3-yl)pyridin-2-amine.

58. The compound of any one of claims 1-4, represented by Formula (IB):



Formula (IB)

wherein,

each A, A¹ and A² is the same or different and independently -N=, -CR⁵=, or -O-;

each R³, R⁴ and R⁵ is independently hydrogen or alkyl;

L is heteroaryl or heterocycle;

R⁷ is hydrogen, alkyl, alkoxy, or halo;


X is -O-, -NR⁸-, or -C(R⁹)₂-;

R⁸ is hydrogen, alkyl, or -C(O)R¹⁰-;

each R⁹ is independently hydrogen, alkyl, alkoxy, or halo; and

R¹⁰ is alkyl, cycloalkyl, aryl, alkoxy, or aralkyl.

59. The compound of claim 58, represented by Formula (IB1):



Formula (IB1)

wherein,

each A, A¹ and A² is the same or different and independently -N=, -CR⁵=, or -O-;

R¹ is aryl, heteroaryl, cycloalkyl, heterocyclyl, aralkyl, or cycloalkylalkyl;

each of R³, R⁴ and R⁷ is hydrogen,


R⁸ is hydrogen, alkyl, or -C(O)R¹⁰-; and

R¹⁰ is alkyl, cycloalkyl, aryl, alkoxy, or aralkyl.

60. The compound of claim 59 wherein R¹ is aryl, aralkyl, heteroaryl or cycloalkylalkyl.

61. The compound of claim 59 wherein R¹ is pyridinyl, substituted pyridinyl, pyrazinyl, substituted pyrazinyl, thiazolyl, substituted thiazolyl, phenyl, substituted phenyl, benzyl or cyclopropylalkyl.

62. The compound of claim 58, represented by Formula (IB2):



Formula (IB2)


wherein,

each A, A¹ and A² is the same or different and independently -N=, -CR⁵=, or -O-;

R¹ is aryl, heteroaryl, cycloalkyl, or heterocyclyl; and

each of R³, R⁴ and R⁷ is hydrogen.

63. The compound of claim 58, represented by Formula (IB3):



each A, A¹ and A² is the same or different and independently -N=, -CR⁵=, or -O-;

R¹ is aryl, heteroaryl, cycloalkyl, or heterocyclcyl; and each of R³, R⁴, R⁷ and R⁹ is hydrogen;

64. A pharmaceutical composition comprising a compound of any one of claims 1-63 and a pharmaceutically acceptable excipient.

65. Use of a pharmaceutically effective amount of a compound of any one of claims 1-63 or a pharmaceutical composition of claim 64 in the manufacture of a medicament for treating leukemia and lymphomas in a subject in need thereof.

66. Use of a pharmaceutically effective amount of a compound of any one of claims 1-63 or a pharmaceutical composition of claim 64 in the manufacture of a medicament for treating endometriosis in a subject in need thereof.

67. Use of a pharmaceutically effective amount of a compound of any one of claims 1-63 or a pharmaceutical composition of claim 64 in the manufacture of a medicament for treating restenosis in a subject in need thereof.

68. Use of a pharmaceutically effective amount of a compound of any one of claims 1-63 or a pharmaceutical composition of claim 64 in the manufacture of a medicament for treating atherosclerosis/thrombosis in a subject in need thereof.

69. Use of a pharmaceutically effective amount of a compound of any one of claims 1-63 or a pharmaceutical composition of claim 64 in the manufacture of a medicament for treating psoriasis in a subject in need thereof.

70. Use of a pharmaceutically effective amount of a compound of any one of claims 1-63 or a pharmaceutical composition of claim 64 in the manufacture of a medicament for treating age-related macular degeneration or diabetic retinopathy in a subject in need thereof.

71. Use of a pharmaceutically effective amount of a compound of any one of claims 1-63 or a pharmaceutical composition of claim 64 in the manufacture of a medicament for treating retinopathy of prematurity in a subject in need thereof.

72. Use of a pharmaceutically effective amount of a compound of any one of claims 1-63 or a pharmaceutical composition of claim 64 in the manufacture of a medicament for treating renal transplant rejection in a subject in need thereof.

73. Use of a pharmaceutically effective amount of a compound of any one of claims 1-63 or a pharmaceutical composition of claim 64 in the manufacture of a medicament for treating rheumatoid arthritis in a subject in need thereof.

74. Use of a pharmaceutically effective amount of a compound of any one of claims 1-63 or a pharmaceutical composition of claim 64 in the manufacture of a medicament for treating osteoarthritis in a subject in need thereof.

75. Use of a pharmaceutically effective amount of a compound of any one of claims 1-63 or a pharmaceutical composition of claim 64 in the manufacture of a medicament for treating osteoporosis in a subject in need thereof.

76. Use of a pharmaceutically effective amount of a compound of any one of claims 1-63 or a pharmaceutical composition of claim 64 in the manufacture of a medicament for treating cataracts in a subject in need thereof.

77. Use of a pharmaceutically effective amount of a compound of any one of claims 1-63 or a pharmaceutical composition of claim 64 in the manufacture of a medicament for treating metastasized tumors in a subject in need thereof.